Piramal Enterprises is currently trading at Rs. 1359.60, up by 17.00 points or 1.27% from its previous closing of Rs. 1342.60 on the BSE.
The scrip opened at Rs. 1357.00 and has touched a high and low of Rs. 1364.90 and Rs. 1303.00 respectively. So far 135788 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 2,049.50 on 04-Jul-2019 and a 52 week low of Rs. 608.00 on 24-Mar-2020.
Last one week high and low of the scrip stood at Rs. 1370.20 and Rs. 1164.50 respectively. The current market cap of the company is Rs. 29972.91 crore.
The promoters holding in the company stood at 46.06%, while Institutions and Non-Institutions held 39.11% and 14.83% respectively.
CA Clover Intermediate II Investments, an affiliated entity of CAP V Mauritius, an investment fund managed and advised by affiliated entities of The Carlyle Group Inc. has agreed to invest fresh equity capital for a 20% stake in Piramal Enterprises’ wholly owned subsidiary — Piramal Pharma. The estimated equity capital investment in Piramal Pharma would amount to over Rs 3,700 crore. The final amount of equity investment will depend on the net debt, exchange rate and performance against the pre-agreed conditions at the time of closing of the deal.
Piramal Enterprises is one of India’s large diversified companies, with a presence in Pharmaceuticals, Healthcare Information Management and Financial Services.
